Precision Antibody, a leader in custom monoclonal antibody development, announces its participation in the Targeted Therapies Licensing & Partnering Summit Asia 2026, taking place February 26–27, 2026, in Meguro-ku, Tokyo, Japan.

Precision Antibody will attend the partnering-focused meeting alongside A&G Pharmaceutical, Inc., engaging with biopharmaceutical companies, investors, and research leaders to explore strategic collaborations in targeted therapies and antibody-based drug development.

The Targeted Therapies Licensing & Partnering Summit Asia is a premier event designed to facilitate high-value business development discussions, licensing opportunities, and cross-border partnerships within oncology and precision medicine. The summit provides a dedicated platform for companies advancing innovative therapeutic assets to connect with potential partners across Asia and globally.

Precision Antibody brings to the meeting its extensive expertise in custom monoclonal antibody development, including fully human antibody generation and biomarker-focused antibody solutions that support therapeutic and translational research initiatives.

“Partnering meetings like this play a critical role in accelerating innovation,” said Dr. Serrero. “We look forward to engaging with potential collaborators in Tokyo and exploring opportunities to advance targeted therapy programs through strategic partnerships.”

As biomarker antibody specialists, Precision Antibody has established a strong track record in developing high-quality, high-affinity monoclonal antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute’s Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

Through its collaboration-driven approach and commitment to scientific excellence, Precision Antibody continues to support biopharma partners in accelerating the discovery and development of next-generation targeted therapeutics.

Attendees of the Targeted Therapies Licensing & Partnering Summit Asia 2026 are invited to connect with representatives from Precision Antibody and A&G Pharmaceutical to discuss licensing opportunities, co-development partnerships, and strategic collaborations.

About Precision Antibody

Founded in 2000, Precision Antibody is a U.S.-based biotechnology company specializing in the rapid development of custom monoclonal antibodies. Known for delivering antibodies that work “right the first time,” the company supports pharmaceutical, biotech, academic, and government researchers worldwide. With a proven track record in biomarker antibody development and contributions to the NCI’s Clinical Proteomic Technologies for Cancer (CPTC) program, Precision Antibody is recognized for setting benchmarks in antibody quality and reliability. In 2025, the company was honored as the Best Monoclonal Antibody Development Company, reinforcing its leadership and commitment to advancing diagnostics, therapeutics, and translational research through high-performance, royalty-free antibodies.